Investor Presentaiton

18 Darovasertib Monotherapy in (Neo)adjuvant Primary Uveal Melanoma Clinical Experience: Observed 100% of Patients (9 of 9) with Ocular Tumor Reduction^ IDEAYA Phase 2 and IST ongoing to evaluate Darovasertib Current Treatment Approach following diagnosis of UM depends on tumor size and location: Enucleation in Large Tumors (~ 20%) Radiation in Small/Medium Tumors (~80%) Plaque Brachytherapy Clinical Experience in UM and MUM Patients Neoadjuvant UM Enucleation Cohort ** (n=6) Treatment Duration (mo) MUM Intact Primary Ocular Tumors* (n=3) Plaque Placement lodine-125 Plaque Surgery, UCLA Poor Vision (≤20/200) occurs in about 70%-80% of patients with UM (including enucleation) Neoadjuvant / Adjuvant Systemic Therapy goals: Avoid Nucleation → Save the Eye Reduce Tumors and Radiation Dose → Protect Vision Reduce Occurrence of Metastasis → Save Lives Paradigm Shifting Opportunity to Broadly Impact UM, with annual incidence of ~8,000 - 10,000 patients in US, EU + Neoadjuvant UM or MUM patients treated with Darovaserib + Crizotinib Best Ocular Tumor Response (%) 1 1 0% -10% -20% -30% -40% Treatment Duration (mo) Γ I 2 4 1 4 7 0.5 11 I 0% -10% -20% + -30% I -60% Eye Saved -40% -50% -60% I -70% I + -80% | Eye -90% Saved -100% -50% -70% -80% -90% I CASE STUDIES + Darovasertib + Crizotinib + Each Reported Case has shown a Reduction in Size of Ocular Eye Lesion ** Data by investigator assessment as of April 15, 2023, from (i) NADOM IST courtesy of Professor Anthony Joshua, MBBS, PhD, FRACP, St. Vincent's Hospital, with update as of June 22, 2023 for monotherapy NADOM IST patient who was spared enucleation (ii) Compassionate Use Case; for NADOM IST, by initial protocol the first 3 neoadjuvant UM patients were required to stop treatment at ~1 month; IST protocol was subsequently amended to treat up to 6 months ^ Best Ocular Tumor Response based on maximal % reduction in measured Apical Height or Longest Basal Diameter (LBD) * Ocular tumor shrinkage measured by investigator assessment by either MRI, ultrasound, CT-scan, or PET scan (0.5 month scan for MUM patient, SUV Max% tumor response) IDEA A BIOSCIENCES

View entire presentation